On or around 09/05/2019 (Notice of voluntarily dismissal)
Filing Date: March 11, 2019
According to Complaint, this action stems from a proposed transaction announced on February 25, 2019, pursuant to which Spark Therapeutics, Inc. will be acquired by Roche Holdings, Inc. and 022019 Merger Subsidiary, Inc. On February 22, 2019, Spark’s Board of Directors caused the Company to enter into an agreement and plan of merger with Roche. Pursuant to the terms of the Merger Agreement, Merger Sub commenced a tender offer to acquire all of Spark’s outstanding common stock for $114.50 per share in cash. The Tender Offer is set to expire on April 3, 2019.
On March 7, 2019, defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.
This case was voluntarily dismissed on September 5, 2019.
Company & Securities Information
Defendant: Spark Therapeutics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: ONCE
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Michael Kent, et al. v. Spark Therapeutics, Inc., et al.
COURT: D. Delaware
DOCKET #: 19-CV-00485
JUDGE: Hon. Colm F. Connolly
DATE FILED: 03/11/2019
CLASS PERIOD START: 02/25/2019
CLASS PERIOD END: 03/11/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Rigrodsky & Long, P.A. (Wilmington)
RM Law, P.C.
First Identified Complaint (FIC) Filings:
Complaint for Violation of the Securities Exchange Act of 1934
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available